MB
MPM BioImpact Portfolio holdings
AUM
$577M
This Quarter Return
-10.74%
1 Year Return
+8.33%
3 Year Return
+241.63%
5 Year Return
+127.38%
10 Year Return
–
AUM
$582M
AUM Growth
+$582M
(-17%)
Cap. Flow
-$7.77M
Cap. Flow
% of AUM
-1.34%
Top 10 Holdings %
Top 10 Hldgs %
47.58%
Holding
53
New
6
Increased
26
Reduced
8
Closed
10
Top Buys
| 1 |
Madrigal Pharmaceuticals
MDGL
|
$33.3M |
| 2 |
ARS Pharmaceuticals
SPRY
|
$16.5M |
| 3 |
Alkermes
ALKS
|
$11.1M |
| 4 |
United Therapeutics
UTHR
|
$11.1M |
| 5 |
Janux Therapeutics
JANX
|
$9.1M |
Top Sells
| 1 |
Insmed
INSM
|
$26.9M |
| 2 |
Mirum Pharmaceuticals
MIRM
|
$24.4M |
| 3 |
Disc Medicine
IRON
|
$22M |
| 4 |
Scholar Rock
SRRK
|
$18M |
| 5 |
Akero Therapeutics
AKRO
|
$12.8M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Xenon Pharmaceuticals
XENE
$2.98B
| $10.2M | 1.75% | 303,398 +106,186 | +54% | +$3.56M |
|
27
Vera Therapeutics
VERA
$1.38B
| $9.99M | 1.72% | 415,719 +157,931 | +61% | +$3.79M |
|
28
Replimune Group
REPL
$422M
| $9.62M | 1.65% | 987,036 +37,036 | +4% | +$361K |
|
29
Iovance Biotherapeutics
IOVA
$807M
| $9.02M | 1.55% | 2,708,582 +34,677 | +1% | +$115K |
|
30
Context Therapeutics
CNTX
$75.4M
| $9M | 1.55% | 14,705,882 | – | – |
|
|
MBX
31
MBX Biosciences, Inc. Common Stock
MBX
$507M
| $8.36M | 1.44% | +1,132,950 | New | +$8.36M |
|
32
Nuvation Bio
NUVB
$1.02B
| $8.19M | 1.41% | 4,652,243 +488,065 | +12% | +$859K |
|
33
Oric Pharmaceuticals
ORIC
$994M
| $7.81M | 1.34% | +1,399,514 | New | +$7.81M |
|
34
IDEAYA Biosciences
IDYA
$2.15B
| $7.05M | 1.21% | 430,161 +16,126 | +4% | +$264K |
|
35
Solid Biosciences
SLDB
$427M
| $6.08M | 1.04% | +1,642,356 | New | +$6.08M |
|
36
Relay Therapeutics
RLAY
$619M
| $6.02M | 1.03% | 2,295,924 +27,099 | +1% | +$71K |
|
37
Stoke Therapeutics
STOK
$1.08B
| $4.62M | 0.79% | 693,988 +8,162 | +1% | +$54.3K |
|
38
Veru
VERU
$47.6M
| $3.23M | 0.56% | 6,592,727 +2,307,362 | +54% | +$1.13M |
|
39
Werewolf Therapeutics
HOWL
$59.9M
| $2.34M | 0.4% | 2,408,810 +20,799 | +0.9% | +$20.2K |
|
40
Design Therapeutics
DSGN
$315M
| $2.17M | 0.37% | 562,943 +3,396 | +0.6% | +$13.1K |
|
|
ADAP
41
Adaptimmune Therapeutics
ADAP
$15.6M
| $964K | 0.17% | 4,894,344 -201,568 | -4% | -$39.7K |
|
42
Repare Therapeutics
RPTX
$71.7M
| $808K | 0.14% | 819,924 -411,230 | -33% | -$405K |
|
43
ALX Oncology
ALXO
$62.7M
| $343K | 0.06% | 550,000 -841,434 | -60% | -$524K |
|
|
44
Akero Therapeutics
AKRO
$3.74B
| – | – | -460,617 | Closed | -$12.8M |
|
45
Aquestive Therapeutics
AQST
$456M
| – | – | -1,611,833 | Closed | -$5.74M |
|
46
Arcturus Therapeutics
ARCT
$462M
| – | – | -459,943 | Closed | -$7.81M |
|
47
Axsome Therapeutics
AXSM
$6.05B
| – | – | -50,000 | Closed | -$4.23M |
|
|
48
Insmed
INSM
$28.8B
| – | – | -389,611 | Closed | -$26.9M |
|
|
49
Disc Medicine
IRON
$2.07B
| – | – | -346,401 | Closed | -$22M |
|
|
50
Mirum Pharmaceuticals
MIRM
$3.71B
| – | – | -589,579 | Closed | -$24.4M |
|